– Reports total Q1 2026 revenue of $3.4 million, representing year-over-year growth of 122% – – Received IDE approval from FDA to initiate the CGUARDIANS III clinical trial of its SwitchGuard neuro protection system for use in TCAR procedures –             – FDA approval of the original CGuard delivery system anticipated in Q3 2026 – – On track for expected FDA approval of the CGuard Prime 80 cm for TCAR procedures in H2 2026, potentially doubling the Company’s addressable market – MIAMI, May 04, 2026 (GLOBE NEWSWIRE) — InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced financial and operating results for the first quarter ended March 31, 2026. Recent Business...

Year-over-year operating income growth outpaces revenue growth by 2x SCOTTSDALE, Ariz., May 04, 2026 (GLOBE NEWSWIRE) — onsemi (the “Company”) (Nasdaq: ON) today announced its first quarter 2026 results with the following highlights:Revenue of $1,513 million, exceeding the midpoint of our guidance GAAP and non-GAAP gross margin of 38.5% GAAP operating margin of (3.5)% and non-GAAP operating margin 19.1% GAAP diluted loss per share of ($0.08) and non-GAAP diluted earnings per share $0.64 Share repurchases of $346 million, representing approximately 160% of free cash flow“We exceeded expectations as demand strengthened through the quarter and we have moved beyond the cyclical trough on a path to recovery. Our AI data center business accelerated, growing more than 30% sequentially.” said Hassane El‑Khoury, President and CEO of...

CHAPEL HILL, N.C., May 04, 2026 (GLOBE NEWSWIRE) — Chapel Hill, N.C., May 4, 2026 – James River Group Holdings, Inc. (“James River” or the “Company”) (NASDAQ: JRVR) today reported the following results for the first quarter of 2026 as compared to the same period in 2025:  Three Months EndedMarch 31,   Three Months EndedMarch 31,($ in thousands, except for share data)   2026     per diluted share     2025     per diluted shareNet (loss) income from continuing operations available to common shareholders $ (10,743 )   $ (0.23 )   $ 9,019     $ 0.18  Net loss from discontinued operations1   (149 )   $ —       (1,414 )   $ (0.02 )Net (loss) income available to common shareholders   (10,892 )   $ (0.23 )     7,605     $ 0.16  Adjusted net operating income2   5,806     $ 0.12       9,102     $ 0.19  Unless...

Announced selection of rinzimetostat RP3D in combination with darolutamide for Himalayas-1 Phase 3 global registrational trial in post-abiraterone mCRPC, expected to initiate in 1H 2026 Reported rinzimetostat data in post-abiraterone mCRPC supporting potential best-in-disease profile, including a highly differentiated safety profile and landmark rPFS consistent with competitor PRC2 inhibitor and substantially better than standard of care therapies in mCRPC Reported early rinzimetostat data in post-AR inhibitor mCRPC, demonstrating promising durability and reinforcing rinzimetostat’s potential to restore and sustain the benefit derived from AR inhibitors Anticipate rinzimetostat program update in 2H 2026 and several enozertinib clinical updates in 2H 2026 ahead of potential initiation of a registrational trial Cash and investments of approximately...

Signed new license agreements with AMD and MicrosoftGenerated $58 million in cash from operations and achieved 60% adjusted EBITDA marginPaid down debt by $28 million bringing our outstanding balance to less than $400 million SAN JOSE, Calif., May 04, 2026 (GLOBE NEWSWIRE) — Adeia Inc. (Nasdaq: ADEA) (the “Company” or “Adeia”) today announced financial results for the first quarter ended March 31, 2026. “We had a strong start to 2026, delivering first quarter revenue of $105 million, generating $58 million in operating cash flow, and maintaining strong profitability with a 60% adjusted EBITDA margin,” said Paul E. Davis, chief executive officer of Adeia. “We closed eight license agreements during the quarter, three of which were with new customers, including multi-year agreements with AMD and Microsoft. We believe our deal execution...

BOULDER, Colo., May 04, 2026 (GLOBE NEWSWIRE) — Gaia, Inc. (NASDAQ: GAIA), a conscious media and community company, reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Summary vs First Quarter 2025 (where applicable)Revenue increased to $24.3 million compared to $23.8 million. Gross profit remained flat at $20.9 million. Generated $1.5 million in operating cash flow and $1.1 million in free cash flow.Management Commentary “This quarter reflects a deliberate step in how we are positioning Gaia for long-term success,” said Kiersten Medvedich, Chief Executive Officer of Gaia. “As we’ve evaluated the business, it has become clear that our greatest opportunity lies in deepening our direct relationship with members, where we can deliver the full Gaia experience and capture significantly stronger...

Grows Q1 revenue 15% year-over-year to $190.9 million Delivers net income of $18.7 million Drives record Adjusted EBITDA of $29.3 million, marking growth of 30% year-over-year Exceeds guidance across all metrics Provides Q2 outlook reflecting 21% revenue growth at the midpointCAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) — EverQuote, Inc. (Nasdaq: EVER), a leading provider of growth solutions for property and casualty, or P&C, insurance providers, today announced financial results for the first quarter ended March 31, 2026. “Our first quarter results demonstrate our strong performance and favorable sector demand as we execute our mission to empower P&C insurance providers to grow market share by maximizing customer acquisition across digital channels,” said Jayme Mendal, CEO of EverQuote. “As we look to the remainder...

GAAP Net Loss of $0.33 Per Diluted Share for the First Quarter FFO, As Adjusted of $0.15 Per Diluted Share for the First Quarter Office Same Store NOI Growth of 0.7% (Cash)Positive Office New Lease Spreads of 9.6% (GAAP) and 7.2% (Cash) Retail Same Store NOI Growth of 2.2% (Cash)Positive Retail Renewal Spreads of 10.7% (GAAP) and 4.5% (Cash) VIRGINIA BEACH, Va., May 04, 2026 (GLOBE NEWSWIRE) — AH Realty Trust (NYSE: AHRT) today announced its results for the quarter ended March 31, 2026 and provided an update on current events and earnings guidance. First Quarter and Recent Highlights:On February 16, 2026, we announced a fundamental business restructuring to eliminate complexity, strengthen the balance sheet, and relentlessly focus on operating a streamlined real estate platform. The restructuring includes:Exiting the multifamily...

MINNEAPOLIS, May 04, 2026 (GLOBE NEWSWIRE) — Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Summary and Recent Business Highlights:Total revenue increased 23% year-over-year to $75.3 million Gross margin of 76.5% versus 74% in Q1 2025 Net loss of $1.8 million versus $3.0 million in Q1 2025 Adjusted EBITDA of $3.7 million versus an Adjusted EBITDA loss of $0.3 million in Q1 2025 Expanded AI-enabled order management platform with the implementation of new operational capabilities to execute the Medicare prior authorization requirement for PCDs Repurchased $1.1 million of stock under the Company’s share repurchase program Received...

– Company to Host Conference Call on May 12, 2026, at 4:30 p.m. ET – SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that it will release its financial results for the first quarter ended March 31, 2026, after the market close on Tuesday, May 12, 2026. Management will host a conference call and webcast at 4:30 p.m. ET that same day.Title:Capricor Therapeutics First Quarter 2026 Financial Results and Recent Corporate Update Conference Call and WebcastDate:Tuesday, May 12, 2026Time:4:30 p.m. ETCall Details:Toll-Free: 1-800-717-1738International: 1-646-307-1865Conference ID: 60968 Participants may dial in using the numbers above and ask to be...